Market eyes KIP's Global Pharma PEF The fund with 135 billion won committed capital is likely to generate high returns
Translated by Kim So-in 공개 2019-10-15 08:00:00
이 기사는 2019년 10월 15일 08:00 thebell 에 표출된 기사입니다.
South Korea's Pharmaceutical and Bio-Pharma private equity fund (PEF), managed by Korea Investment Partners (KIP) is gaining attention. The big fund is anticipated to generate high returns amid a boom in pharmaceutical and bio-pharma industry.According to industry sources on October 7, 'Korea Investment Global Pharmaceutical Industry Promotion Private Equity Fund (Global Pharma PEF)' invested 12 billion won in TiumBio and owns over 3.62 million shares. TiumBio kicked off its initial public offering (IPO) on KOSDAQ. Based on the bottom end of the IPO pricing range, Global Pharma PEF's shares are worth around 58 billion won.
Global Pharma PEF was created in 2015 with 135 billion won in committed capital. It was part of the Ministry of Health and Welfare (MOHW)'s project to promote and nurture pharmaceutical and bio-pharma companies whose technology is promising but capital strength is weak. MOWH (20 billion won), Korea Finance Corporation (50 billion won), Korea Investment & Securities (10 billon won), KIP (20 billion) invested in the PEF.
Targeting domestic and overseas pharmaceutical and bio-pharma companies, the fund has deployed over 120 billion won. Funds managed by venture capital firms normally spend 85~90 percent of total commitments, considering management fee and operating cost.
The fund invested 5 billion won in Ahngook Pharm and AGBIO Diagnostics, respectively and 10 billion won in Handok Kalos Medical. It also invested in three affiliates of Huons Group - Huons Medicare, Huons Natural, and Biotopia.
Global Pharma PEF's investment ranges from mezzanines issued by listed companies to equity investment in private companies. Most of the listed companies, such as HLB, Lego Chem Bio, and CTC Bio have a long history with the PEF.
Among private companies, the fund invested in ABL Bio (11 billion won), Denflex (2 billion won), Precision Biosensor (2.4 billion won), TiumBio (9 billion won), Gencurix (2 billion won), BioSynetics (3 billion won), and Genome & Company (4 billion won). The fund also invested in the overseas bio-pharma companies, such as Elastagen in Australia (5 million dollar) and Eloxx Pharmaceutical in Israel (4.4 billion won).
ABL Bio, which the fund strategically invested in, like it did with TiumBio, made its stock market debut last year. The fund owns over 3.8 million shares in the company, which equates to 68 billion won based on the current stock price of 18 thousand won. In April, the fund sold its shares in ABL Bio for approximately 60 billion won. TiumBio and ABL Bio alone already surpass committed capital.
The fund also exited its investment in Elastagen with Allergan's acquisition of Elastagen, returning multiple of four times. The fund also exited from HLB.
"It is hard for funds with large capital commitments to record high returns compared with fund with small commitments. As far as I know, Global Pharma PEF has a unique strategy for high returns, which begins with incubating promising bio-pharma companies," said one venture capital industry source.
(By reporter Lee Youn-jae)
< 저작권자 ⓒ 자본시장 미디어 'thebell', 무단 전재, 재배포 및 AI학습 이용 금지 >
best clicks
최신뉴스 in 전체기사
-
- [보험경영분석]ABL생명, 투자부문 금리효과에 흑자…진짜는 '회계효과'
- [여전사경영분석]JB우리캐피탈, 고수익 자산 중심 포트폴리오 개편 지속
- [보험사 IFRS17 조기도입 명암]에이스손보, 지급여력비율 개선의 이면 '계약감소'
- [보험 패러다임 시프트]IFRS17에 바뀐 경영전략…'퍼스트 무버' 총력전
- [보험사 해외사업 점검]삼성생명, 성장 느린 태국법인…자산운용 투자 '속도'
- [2금융권 연체 리스크]현대카드, 최상위 건전성 지표…현금서비스·리볼빙 주의
- [보험사 IFRS17 조기도입 명암]DB손보, 새 제도 도입 후 계약부채 확 줄었다
- [보험사 IFRS17 조기도입 명암]AIG손보, 장기보험 비중확대 전략의 양면성
- [금융지주 해외은행 실적 점검]대구은행 캄보디아 법인, 법률 리스크 딛고 '성장일로'
- [보험사 IFRS17 조기도입 명암]신한EZ, 손익 변동 미미…부실 이익체력은 부각